Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne Bellemain

Showing results (1-10 of 38) with videos related to

Pageof 4
Sort By:
Presse Medicale (Paris, France : 1983)|May 2, 2008
[New antiplatelet drugs]Anne Bellemain, Jean-Philippe Collet, Gilles Montalescot
Presse Medicale (Paris, France : 1983)|April 23, 2011
[Myocardial infarction: Role of new antiplatelet agents]Johanne Silvain, Anne Bellemain, Patrick Ecollan, et al.
Journal of the American College of Cardiology|August 31, 2010
New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysisAnne Bellemain-Appaix, David Brieger, Farzin Beygui, et al.
Circulation. Cardiovascular Interventions|October 6, 2011
CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patientsJean-Sébastien Hulot, Jean-Philippe Collet, Guillaume Cayla, et al.
The American Journal of Cardiology|August 21, 2010
Usefulness of biomarker strategy to improve GRACE score's prediction performance in patients with non-ST-segment elevation acute coronary syndrome and low event ratesFarzin Beygui, Johanne Silvain, Ana Pena, et al.
Journal of the American College of Cardiology|July 13, 2010
Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysisJean-Sébastien Hulot, Jean-Philippe Collet, Johanne Silvain, et al.
Case Reports in Cardiology|September 13, 2021
Anomalous Left Coronary Artery Connected to the Pulmonary Artery in a 15-Year-Old Girl: Case Report and Discussion on Secondary Prevention of Sudden DeathJérémy Laïk, Virginie Fouilloux, Philippe Aldebert, et al.
European Journal of Heart Failure|May 1, 2020
Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patientsJennifer Cautela, Jean-Michel Tartiere, Alain Cohen-Solal, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|December 14, 2011
Bleeding complications in primary percutaneous coronary intervention of ST-elevation myocardial infarction in a radial centerOlivier Barthélémy, Johanne Silvain, David Brieger, et al.
JAMA|January 5, 2013
Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysisAnne Bellemain-Appaix, Stephen A O'Connor, Johanne Silvain, et al.
Pageof 4

Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
Presse Medicale (Paris, France : 1983)|May 2, 2008
[New antiplatelet drugs]Anne Bellemain, Jean-Philippe Collet, Gilles Montalescot
Presse Medicale (Paris, France : 1983)|April 23, 2011
[Myocardial infarction: Role of new antiplatelet agents]Johanne Silvain, Anne Bellemain, Patrick Ecollan, et al.
Journal of the American College of Cardiology|August 31, 2010
New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysisAnne Bellemain-Appaix, David Brieger, Farzin Beygui, et al.
Circulation. Cardiovascular Interventions|October 6, 2011
CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patientsJean-Sébastien Hulot, Jean-Philippe Collet, Guillaume Cayla, et al.
The American Journal of Cardiology|August 21, 2010
Usefulness of biomarker strategy to improve GRACE score's prediction performance in patients with non-ST-segment elevation acute coronary syndrome and low event ratesFarzin Beygui, Johanne Silvain, Ana Pena, et al.
Journal of the American College of Cardiology|July 13, 2010
Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysisJean-Sébastien Hulot, Jean-Philippe Collet, Johanne Silvain, et al.
Case Reports in Cardiology|September 13, 2021
Anomalous Left Coronary Artery Connected to the Pulmonary Artery in a 15-Year-Old Girl: Case Report and Discussion on Secondary Prevention of Sudden DeathJérémy Laïk, Virginie Fouilloux, Philippe Aldebert, et al.
European Journal of Heart Failure|May 1, 2020
Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patientsJennifer Cautela, Jean-Michel Tartiere, Alain Cohen-Solal, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|December 14, 2011
Bleeding complications in primary percutaneous coronary intervention of ST-elevation myocardial infarction in a radial centerOlivier Barthélémy, Johanne Silvain, David Brieger, et al.
JAMA|January 5, 2013
Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysisAnne Bellemain-Appaix, Stephen A O'Connor, Johanne Silvain, et al.
Pageof 4